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Abstract: The role of the gut microbiome in human health and disease is the focus of much attention.
It has been widely agreed upon that our gut bacteria play a role in host immunity, nutrient absorption,
digestion, metabolism, and other key drivers of health. Furthermore, certain microbial signatures
and specific taxa have also been associated with the development of diseases, such as obesity;
inflammatory bowel disease; and, indeed, colorectal cancer (CRC), which is the focus of this review.
By extension, such taxa represent potential therapeutic targets. In particular, the emerging human
pathogen Fusobacterium nucleatum represents an important agent in CRC development and its control
within the gastrointestinal tract is desirable. This paper reviews the principal bacterial pathogens
that have been associated with CRC to date and discusses the in vitro and human studies that have
shown the potential use of biotherapeutic strains as a means of targeting CRC-associated bacteria.
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1. Introduction
Colorectal cancer (CRC) refers to cancer of the rectum or colon [1]. CRC accounts for 9.2% of
all cancer diagnoses globally, corresponding to 1.096 million cases, and is the second leading cause
of cancer-related deaths worldwide [2]. Colorectal tumorigenesis is attributed to genomic and/or
epigenomic instability, resulting in the formation of neoplastic lesions [3,4]. More specifically, such
instabilities can promote mutations that result in the inactivation of tumour suppressor genes and the
activation of oncogenes, leading to colonic cell malignancies [5]. Risk factors for CRC include excessive
alcohol consumption, smoking, and lack of exercise, and epidemiological studies have shown diets
rich in red meat and animal fat may also promote CRC development [6] whereas a diet heavy in fruit
and vegetables can have a protective effect [7]. Strong evidence has also been put forward for a role of
specific human gut microbes in CRC development and progression [8–11].
Despite the advances in cancer therapeutics, including surgery and chemotherapy [12,13], in
recent years, CRC remains one of the most aggressive and invasive malignancies [14]. Chemotherapy
can damage healthy cells including hair follicle cells, mucous membranes of oral cavities, and the
gastrointestinal tract, adversely affecting erythrocytes and leukocytes [15]. Surgical procedures such as
colectomies may disrupt the resident gut microbiota, favouring the growth of harmful bacteria [16].
Therefore, nontoxic, noninvasive alternative therapeutics and, indeed, preventative approaches are
highly desirable.
In this review, the microbial influence on the development of CRC is examined, with a focus
on bacterial pathogens such as the emerging human pathogen Fusobacterium nucleatum that has been
recently strongly associated with colon tumorigenesis. Bacterial strains that inhibit the CRC-associated
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pathogen F. nucleatum and that reduce CRC-associated taxa within the gut microbiota and, therefore,
have the potential to contribute to CRC prevention by acting as biocontrol agents are also discussed.
2. The Gut Microbiota of CRC Patients
The gut microbiome contains over 100 trillion microbes that play crucial roles in host health, and the
maintenance of gut homeostasis is largely dependent on the symbiotic interactions between microbes
and the digestive tract [17], while an imbalance in the gut microbiome can promote the secretion of
bacterial toxins (virulence factors) and carcinogenic metabolites (hydrogen sulfide), decrease beneficial
metabolites (butyrate), compromise the intestinal barrier function, cause immune dysregulation, and
lead to cellular proliferation which can contribute to CRC [18].
Many studies have assessed the gut microbiome of CRC patients, revealing a number of
patterns [19]. While there are variations in the microbial composition across different studies, detection
methods, and sample types, several studies have consistently found increased abundances of the genus
Fusobacterium in the gut microbiome of CRC patients [20–26]. While high Fusobacterium abundances
are consistent, several other genera have also been found to be elevated in both tissue and stool
samples of CRC, including Peptostreptococcus [20–22], Streptococcus [20,21,24], Porphyromonas [21,23],
and Selenomonas [21,22]. In contrast, the butyrate (a short chain fatty acid (SCFA))-producing genus
Roseburia is consistently reduced in CRC patients [20–22], while other butyrate-producing taxa were also
underrepresented such as Lachnospiraceae [23] and Ruminococcaceae [25] (Table 1). Some representative
studies are summarised here. For instance, Wang et al. [20] investigated the microbial composition
of CRC patients in comparison to healthy controls using 16S rRNA amplicon (V3) sequencing of
faecal samples. A clear alteration in microbial composition was observed, with an increase in the
relative abundance of the genera Fusobacterium, Enterococcus, Escherichia/Shigella, Klebsiella, Streptococcus,
and Peptostreptococcus and with a reduction in butyrate-producing bacteria, specifically Roseburia,
in CRC patients. In another study, Gao et al. [21] observed similar trends using compositional 16S
rDNA sequencing of cancerous tissue and found increased numbers of Fusobacterium, Streptococcus,
Peptostreptococcus, Porphyromonas, and Selenomonas. Again, low levels of Roseburia were detected in
comparison to healthy controls. Notably, there were significant differences in the relative abundances of
Fusobacterium in malignant tissue compared to noncancerous mucosa, with 8.5% and 4.13%, respectively.
Inconsistencies, however, are also evident between certain studies. For instance, Hibberd et al. [22]
reported an enrichment of Fusobacterium, Peptostreptococcus, and Selenomonas and a depletion of
Roseburia. However, the same study found lower abundances of Streptococcus in the tumour tissue
of CRC patients, which was inconsistent with Gao’s findings. In another study, low abundances of
Lachnospiraceae was significantly associated with CRC [23]. Indeed, Flemer et al. [27] postulated the
protective effects of the butyrate-producing family Lachnospiraceae against CRC in an oral, faecal, and
colonic mucosal metagenomic analysis. Butyrate, an intestinal microbial metabolite, demonstrates
anti-CRC properties through several mechanisms including histone deacetylase (HDAC) inhibition
and epigenetic modulation, which can restrict CRC cell proliferation and can induce apoptosis of CRC
cells [28]. Butyrate plays an important role in host health through maintaining intestinal homeostasis,
reinforcing the epithelial barrier, and inhibiting intestinal inflammation [29]. Thus, the depletion of
butyrate-producing bacteria in the gut microbiota may increase the risk of CRC.
The above subset of studies recognises that there are variations between studies. However,
there are a number of consistent patterns that may provide biomarkers for diagnostic purposes and
may highlight potential therapeutic targets. Reducing abundances of Fusobacterium and increasing
butyrate-producing genera within the gut microbiota may serve as a preventative strategy for CRC.
While high abundances of specific genera are associated with CRC, specific bacterial species have also
been implicated in the disease.
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Table 1. Examples of microbial patterns observed in colorectal cancer (CRC) patients.
Sample Type CRCSamples
Noncancer
Controls Detection Method
Probiotic/Antibiotic
Exclusion Criteria Overrepresented Taxa
Underrepresented
Taxa Reference
Tissue 65 65
16S rRNA gene
(V4)
pyrosequencing
No probiotic or
antibiotic exposure
within 4 weeks
Fusobacterium, Streptococcus,
Peptostreptococcus, Porphyromonas,
and Selenomonas
Roseburia [21]
Tissue 31 b 20
16S rRNA gene
(V3)
pyrosequencing
No antibiotic
exposure within
2 months or probiotic
exposure within
2 weeks
Firmicutes, Fusobacteria,
Lactococcus, and Fusobacterium
Pseudomonas and
Escherichia/Shigella [26]
Tissue 65 65
16S rRNA gene
(V1–V3)
pyrosequencing
- Fusobacterium, Leptotrichia, andCampylobacter
Ruminococcus,
Parabacteroides,
Pseudoflavonifractor,
Ruminococcaceae, and
Holdemania
[25]
Tissue and Mucosa 15 21
16S rRNA gene
(V4) amplicon
sequencing
Recent antibiotic
exposure or regular
use of probiotics
Fusobacterium,
Peptostreptococcus, and
Selenomonas
Roseburia and
Streptococcus [22]
Faecal 9 a 49
Next Generation Sequence (NGS)
analysis & terminal restriction
fragment length polymorphism
(T-RFLP)
Current use of
antibiotics or regular
use of probiotics
Actinomyces, Atopobium,
Fusobacterium, Haemophilus,
Bacteroides fragilis, Clostridium
nexile, Actinomyces odontolyticus
Heamophilus parainfluenzae,
Fusobacterium varium, Prevotella
stercorea, Veillonella dispar, and
Streptococcus gordonii
Slackia and
Eubacterium
coprostanoligens
[24]
Faecal 46 56 16S rRNA gene (V3) pyrosequencing
No antibiotic
exposure within
3 months
Fusobacterium, Enterococcus,
Escherichia/Shigella, Klebsiella,
Streptococcus, and
Peptostreptococcus
Roseburia [20]
Faecal 42 89 16S rRNA gene (V3–V4)pyrosequencing - Fusobacterium and Porphyromonas
Clostridia and
Lachnospiraceae [23]
a Fifty samples from patients with colon adenomas were also obtained. b Samples were segregated into proximal and distal colon samples.
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3. Specific Taxa Associated with CRC Development
Metagenomic analysis have revealed a significant increase in the presence of commensal bacteria
in the gut microbiome of CRC patients including strains of Escherichia coli, Bacteroides fragilis, and
in particular F. nucleatum [30–32]. Studies have also shown that specific species increase the risk of
developing CRC. For example, a 2018 retrospective analysis of 13,096 patients found that CRC risk
was increased in patients with bacteremia caused by B. fragilis, Streptococcus gallolticus, F. nucleatum,
Clostridium septicum, or Clostridium perfringens [33]. Specific bacterial species and several mechanisms
have been implicated in the development of CRC, supporting a causal role. For instance, pathogenic
bacteria may promote CRC through the production of genotoxins and virulence factors, the upregulation
of inflammatory pathways, and the initiation of oxidative stress, which ultimately lead to genetic
instability and epithelial cell proliferation [17]. Therefore, controlling particular components of the
gut may serve to reduce the risk of CRC development. The most extensively studied CRC-associated
bacteria are F. nucleatum, B. fragilis, and E. coli.
3.1. F. nucleatum
F. nucleatum is a Gram-negative and strict anaerobe that predominantly colonises the oral cavity
and is implicated in periodontal diseases such as gingivitis and periodontitis [34]. It is also associated
with many other diseases and adverse health outcomes including inflammatory bowel disease (IBD),
appendicitis, preterm births, stillbirths, atherosclerosis, rheumatoid arthritis, and Alzheimer’s [35–41].
Further to this, F. nucleatum has become an important human pathogen shown to be elevated in
colonic tumours and localised with malignant colonic cells. An increased abundance of Fusobacterium
species has been identified by transcriptomic and metagenomic profiling in colon cancer relative to
healthy tissues [42–45]. Castellarin et al. [42] performed qPCR analysis on tumours of CRC patients
and found an overrepresentation of F. nucleatum when compared to healthy tissue. High numbers
of F. nucleatum have been found to correlate with the progression of colorectal carcinogenesis and
molecular markers such as the CpG island methylator phenotype (CIMP) and colorectal tumours with
evidence of microsatellite instability [46,47]. Park et al. [48] used 16S rRNA sequencing to compare the
gut microbiota of patients with precursors to CRC and patients diagnosed with CRC for the first time.
Mucosal biopsy samples of patients with tubular adenomas (TA), sessile serrated adenomas/polyps
(SSA/P), and CRC revealed no differences in relative abundance of Fusobacteria between TA (4.3%)
and SSA/P (1.9%) groups. However, a significant difference in the relative abundance of Fusobacteria
was observed in the CRC group (33.8%) compared to TA and SSA/P groups. The Fusobacterium–CRC
link was further strengthened, when Rezasoltani et al. [30] found an enrichment of F. nucleatum in
adenomatous polyps compared with healthy matched controls. Ultimately, in 2018, a meta-analysis
which included 122 studies associated high F. nucleatum numbers with the tumorigenesis pathway and
the CpG island methylator phenotype [49]. Over time, evidence has continued to accumulate about
the relationship between F. nucleatum and CRC going beyond a correlation, with the species now being
viewed as a causative agent.
The virulent potential of the species and its ability to disrupt natural cell activities are largely
attributable to FadA, a characterised virulence factor [50]. Rubinstein et al. [51] further characterised
this phenotype as being a promoter of CRC via regulation of E-cadherin (adhesion molecule) and the
transcription factor β-catenin, leading to increased expression of oncogenic and inflammatory genes.
Furthermore, Ma et al. [52] outlined the role of F. nucleatum infection in promoting carcinogenesis
by interacting with E-cadherin in a normal colon epithelial cell line (NCM460) while enhancing
proliferation and activating NF-κB signalling. Furthermore, F. nucleatum increased inflammation and
tumour multiplicity in an ApcMin/+ mouse model of intestinal tumorigenesis [45]. F. nucleatum can
promote inflammatory microenvironments by initiating the release of inflammatory cytokines [53].
Additionally, F. nucleatum can weaken host immune responses as antitumour immunity defences and
natural killer (NK) cells are suppressed by F. nucleatum, ultimately inhibiting tumour killing [54]. Mima
et al. [46] provided further evidence of immunosuppression when they correlated F. nucleatum and
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low-density CD3+ T-cells in colorectal carcinoma tissues. Further to this, F. nucleatum induced M2
polarization of antitumour macrophages, resulting in poor patient prognosis [55]. Causality was also
demonstrated using RNA-seq technologies and functional assays to reveal that autophagy pathways
were activated by F. nucleatum in CRC cells while apoptosis was inhibited. Interestingly, in the same
study, F. nucleatum was shown to promote chemoresistance, which may explain why high abundances
of F. nucleatum correlate with poor patient prognosis [56]. Thymocyte selection-associated high-mobility
group box (TOX) is a highly conserved member of a family of DNA-binding proteins, which plays a role
in cellular functions such as apoptosis, growth, DNA repair, and metastasis [57]. TOX expression was
found to be reduced in F. nucleatum-positive malignant tissues of the colon compared with F. nucleatum
negative tissues. The same study also supported recent findings associating F. nucleatum with low T
cell densities, reporting low CD4+ T cell density in F. nucleatum-positive malignancies compared to
F. nucleatum-negative controls [58].
As noted, the aforementioned findings provide an insight into the role of F. nucleatum in the activation
and progression of tumorigenesis through specific cancer pathways. By extension, reducing F. nucleatum
colonisation in the gut and colon may reduce the risk of CRC development and, once CRC is established,
may slow the progression of the disease. However, other species are also implicated in CRC.
3.2. B. fragilis
B. fragilis is a Gram-negative obligate anaerobe, ubiquitous in nature, and a predominant species
in the gut microbiota [59]. While there are strains of B. fragilis that contribute to gut health and
are being assessed as potential probiotics [60], a possible association between other B. fragilis and
CRC has also been uncovered. For example, Purcell et al. [31] used qPCR analysis to show that
elevated levels of Enterotoxigenic B. fragilis (ETBF) was associated with the early onset of colorectal
carcinogenesis. B. fragilis is thought to promote colon carcinogenesis by stimulating cell proliferation
and by inducing inflammation via the TH17-dependent pathway [61]. ETBF produces a 20-kDa
metalloprotease virulence factor called B. fragilis toxin (BFT) [62]. The expression of BFT in mouse
models induces persistent colitis, interferes with E-cadherin junctions, initiates β-catenin signalling,
and activates IL-8 secretion in colonic epithelial cells (CECs) [63–65]. Sears et al. [66] reported that the
NF-κB signalling pathway is initiated by BFT, leading to increased cell proliferation and initiation of
inflammatory mediators resulting in mucosal inflammation and, ultimately, CRC. Recently, Chung
et al. [67] used an intestinal tumorigenesis mouse model induced by B. fragilis in ApcMin mice to
demonstrate the pro-carcinogenic effects of BFT and its ability to activate NFκB and Stat3, facilitating
tumorigenesis. The presence of the BFT gene has been considered a biomarker for CRC [68] and,
therefore, also highlights a therapeutic target.
3.3. E. coli
E. coli is a natural habitant of the gut microbiota and, in most cases, a commensal organism. Indeed,
some strains are known for their probiotic properties [69], such as the E. coli Nissle 1917 strain. However,
several E. coli strains are known to be encode numerous virulence factors and many studies demonstrate
the genotoxic activities of some E. coli that disrupt natural cellular events and, ultimately, induce
apoptosis [70–74]. E. coli harbouring polyketide synthase (pks) genotoxic islands secrete colibactin, a
bacterial toxin, which may cause DNA damage and promote genomic alterations and instability [75].
Numerous studies have identified elevated levels of E. coli in CRC patients. For example, Bonnet
et al. [32] reported a significant increase in mucosa-associated or internalized E. coli in CRC tumours
compared to noncancerous controls. Furthermore, various levels of cyclomodulin-producing E. coli were
found across different stages of colon cancer, with stages III and IV higher in abundance than stage I.
Metagenomic analysis of patients diagnosed with advanced carcinoma also supports the role of E. coli
in CRC [76]. Arthur et al. [77] provided mechanistic insight by demonstrating that pks+ E. coli NC101
promotes colorectal carcinogenesis in azoxymethane (AOM)-treated IL-10−/− mice. Furthermore, a recent
study identified pks+ E. coli and ETBF to be predominantly colonising biofilms in the colonic mucosa of
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patients diagnosed with familial adenomatous polyposis compared to healthy controls. Interestingly, the
same study showed that mice harbouring both colibactin-secreting E. coli and ETBF showed increased
tumorigenesis compared to mice harbouring E. coli or ETBF individually [78]. These findings suggest
that genotoxin-producing E. coli and B. fragilis could be a synergistic driver of colon cancer.
3.4. Other Bacteria
While other bacteria have been associated with CRC, the evidence for causation is limited and further
studies are needed. For example, the human pathogen Salmonella enterica Serovar Enteritidis (S. enderitidis)
has also been associated with CRC in a limited number of studies. S. enteritidis expresses a secretion
protein, AvrA, which initiates Stat3 and β-catenin signalling pathways, promoting cell proliferation and
tumorigenesis [79]. An epidemiological study found increased risk of developing CRC after S. enteritidis
infection relative to individuals who have not experienced infection by the pathogen [80]. Another
example is Enterococcus faecalis, an emerging human pathogen of the GI tract [81], which was reported to be
significantly more prevalent in patients with CRC compared to healthy control subjects [20,82]. However,
its role in CRC is debated as some studies suggest protective properties; for example, heat-killed E. faecalis
EC-12 was shown to decrease tumour size in the small intestine of a mouse model via downregulating
β-catenin signalling [83]. This paradox likely reflects the considerable differences in the pathogenic
potential of E. faecalis depending on the gene complement present.
In summary, the proposed mechanisms implicating bacterial pathogens in CRC are through
bacterial toxin secretion, activation of inflammatory pathways, disruption of protection barriers, and
interference of natural cellular events, resulting in chronic inflammation and genomic instability, which
can lead to epithelial cellular proliferation and, ultimately, CRC; see Figure 1.
Figure 1. Overview of proposed mechanisms implicating principle CRC-associated bacterial pathogens
in CRC development: Specific bacterial species may promote CRC through several mechanisms, such
as the secretion of virulence factors by F. nucleatum (FadA) and B. fragilis (BFT), which activate NF-kB
and β-catenin signaling pathways, leading to the development of pro-inflammatory cytokines which
promotes pro-inflammatory microenvironments. Virulence factors may interfere with E-cadherin, a
transmembrane protein essential for maintaining the epithelium cell layer, thus mediating the invasion
of pathogenic bacteria. Cyclomodulin and genotoxin-producing E. coli (colibactin) may interfere with
natural cellular events and may induce apoptosis. Biofilms predominantly colonized by genotoxin-
producing E. coli and BFT-producing B. fragilis may be a synergistic driver of CRC. These events
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culminate in the development of chronic inflammation and genomic instability, which leads to epithelial
cellular proliferation and, ultimately, CRC. This figure was created with BioRender.
4. Potential Use of Biotherapeutic Bacteria to Target Colorectal Cancer-Associated Taxa
The need for alternative therapies in this antibiotic resistance era is ever increasing. As the
mechanisms through which specific bacterial species contribute to CRC are revealed, new strategies
can be employed to reduce the growth of these species or, indeed, to eliminate them from the gut
microbiota without harming beneficial bacteria in the process. Probiotics are now widely considered
as a biotherapeutic and are defined as “live microorganisms that, when administered in adequate
amounts, confer a health benefit on the host” [84]. Probiotic bacteria have potential as alternatives
to antibiotics to control undesirable microbes through several mechanisms including antimicrobial
(bacteriocin) production, competition for nutrients, and competitive exclusion of pathogens. Some
antimicrobial-producing probiotics possess narrow spectrum activity against specific pathogenic
bacteria and, thus, do not harm beneficial bacteria within the host microbiota. With regard to CRC,
numerous clinical trials have shown the potential of probiotics as adjuvants, reducing the side effects
associated with chemotherapy and surgeries in CRC-patients [85,86]. The delivery of live biotherapeutic
cells for the treatment of GI diseases is well known and the immunomodulatory and anti-inflammatory
properties of probiotics on colon cancer is well understood [87]; however, few studies exist that
demonstrate the potential of probiotics to eradicate CRC-associated bacteria from the gut microbiome,
consequently reducing the risk of disease development.
5. Antimicrobial Activity of Biotherapeutic Strains against Fusobacterium nucleatum
The correlation between F. nucleatum and CRC has been extensively demonstrated, and the
potential mechanisms underlying the promotion and progression of the disease have been elucidated.
There is little doubt that targeting this organism in the GI tract and that the potential development of
microbiota-targeted therapies against F. nucleatum are promising research avenues. As F. nucleatum
was first identified as a pathogen associated with periodontal disease, numerous studies demonstrate
the potential use of oral strains to inhibit many dental pathogens in vitro, including strains of
F. nucleatum [88–91]. For example, bio-yogurt was shown to have antimicrobial activity against a
range of periodontal pathogens, including the F. nucleatum strains tested. Furthermore, Lactobacillus
bulgaricus, Streptococcus thermophilus, Lactobacillus acidophilus, and Bifidobacterium spp. isolated from
bio-yogurt demonstrated antimicrobial activity against oral pathogens by competition assays. Notably,
Bifidobacterium and Streptococcus thermophilus demonstrated inhibitory activity against F. nucleatum [90].
Another study assessed the antibacterial activity of a number of strains against a range of oral pathogens
by inoculating antimicrobial-producing lactic acid bacteria (LAB) with periodontal pathogens in 96-well
plates and by evaluating growth inhibition by optical density (OD) measurements at 600 nm after 24 h
of anaerobic incubation. Weissella cibaria CMU and two probiotic species isolated from commercial
probiotic products, Lactobacillus salivarius and Lactobacillus reuteri, showed antimicrobial activity against
F. nucleatum with more than 95% growth inhibition compared with other probiotic strains. Interestingly,
W. cibaria CMU demonstrated the highest co-aggregation rate with F. nucleatum with 81.2% as compared
with other cariogenic and periodontopathic bacteria [91]. Co-aggregation, a beneficial property
of probiotics, is a process of attachment which influences multi-species biofilm formation and is
considered a beneficial property of probiotic and other biotherapeutic strains, which may result in
barrier formation that prevents colonisation of pathogenic bacteria [92]. The antimicrobial activity of
probiotics against CRC-associated F. nucleatum has also been assessed in vitro. Guzel-Seydim et al. [93]
reported the anti-F. nucleatum potential of kefir (produced from natural Kefir grains), commercial
Kefir, and yogurt (produced from natural starter cultures) against F. nucleatum by disc diffusion assays.
Natural kefir demonstrated the largest inhibitory effect against F. nucleatum. Kefir produced from
kefir grains is considered a functional food and a source of potential probiotics. Some kefirs and
associated strains have shown specific health benefits [94]. The microbial composition of kefir grains
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is complex; however, the genus Lactobacillus and specifically the species Lactobacillus kefiranofaciens
can dominate [95]. Inhibition of F. nucleatum due to probiotic supplementation is also evident in vivo.
For example, a randomised control trial, which included an oral microbiota analysis, revealed a
reduction in several oral species including F. nucleatum subsp. vincentii after administration of probiotic
strains Lactobacillus reuteri DSM 17,938 and PTA 5289 daily for 12 weeks [96]. Considering, the oral
microbiota’s influence on GI health and disease [97] and that bacteria associated with CRC are also
found in the oral cavity, these findings suggest potential for oral lactobacilli to be active against
CRC-associated F. nucleatum. While these observations are promising, whether the anti-F. nucleatum
activity demonstrated by these strains will translate into the dynamic conditions of the GI tract is yet
to be confirmed. Furthermore, the impact of these anti-F.nucleatum strains on the surrounding gut
microbiota and host health must be evaluated.
6. Probiotic Intervention Modulates the CRC-Associated Microbiome
A reduction in cancer-associated taxa due to the administration of probiotics has also been revealed
through human clinical trials [22,98]. A prospective controlled trial randomised 22 CRC patients
into a group receiving a mixture of Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus
faecalis at a concentration greater or equal to 1.0 × 107 CFU/g three times daily or into a control group
receiving maltodextrin. Samples of mucosa were obtained from colonic tumour sites throughout
surgery, and noncancerous mucosa samples were collected from various colonic areas. Amplification
of the 16S rRNA V3 region and pyrosequencing revealed a significant reduction in Peptostreptococcus
and Comamonas and, most notably, a 5-fold decrease in Fusobacterium numbers after administration of
the probiotic mixture. Additionally, Proteobacteria and Enterococcus were more abundant in patients
receiving probiotic treatment [98]. In another study, the colonic microbiota of CRC patients was
assessed after probiotic intervention with subjects receiving oral tablets twice daily, containing a
high concentration of Bifidobacterium lactis Bl-04 and Lactobacillus acidophilus NCFM, compared to
healthy controls. Faecal samples were collected pre-intervention and, at the time of surgery and 16S
rRNA gene sequencing, were used to evaluate the microbial composition. Analysis revealed strong
differences between the microbial composition of the mucosa and tumour tissue of patients receiving
the probiotic compared to patients receiving no probiotics and to noncancerous controls. The taxa
most associated with CRC, Fusobacterium, and Peptostreptococcus were less represented in the faecal
samples of patients that received the probiotic. Additionally, butyrate-producing taxa Clostridiales spp,
Faecalibacterium, Eubacterium, Roseburia, and Lachnopira were elevated in different sample types obtained
from CRC patients receiving probiotic supplementation [22]. Although these studies were not species
specific, it warrants further investigation into the use of microbial cocktails to control F. nucleatum
and other CRC-associated bacteria. Ultimately, these studies show that strains exhibiting in vitro
activity against F. nucleatum may exist and that there is the possibility that CRC-associated taxa may be
manipulated through probiotic interventional therapy. However, targeting specific species associated
with CRC while leaving beneficial taxa unharmed is desirable. Therefore, the influence of candidate
biotherapeutic bacteria on the overall gut microbiome must be elucidated. Additionally, for the use of
biotherapeutics, such as probiotics to target specific bacteria associated with CRC, they must be able
to survive passage through the harsh conditions of the GI tract and to remain functionally unaltered.
They must be evaluated for resistance to oral cavity enzymes, stomach pH, bile salts, pancreatic juices,
and intestinal mucus while demonstrate an ability to adhere to epithelial tissue. Further investigation
of these and other strains with activity against CRC-associated taxa has considerable merit.
7. Concluding Remarks
Evidence associating bacterial species with CRC is rapidly increasing. Both metagenomic analysis
and mechanistic studies continue to implicate bacterial pathogens in CRC development and disease
progression. Thus, suppressing the growth of CRC-associated bacteria in the gut or colon may provide
a strategy to reduce the overall risk of developing CRC. Further to this, eradicating the pathogens whilst
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leaving the surrounding gut microbiota unharmed is favourable. This may be achieved using narrow
spectrum biotherapeutics, such as bacteriocin-producing probiotics. The above studies demonstrate
the potential use of probiotic bacteria to target F. nucleatum, a bacterial pathogen associated with CRC.
Although results obtained from in vitro studies do not necessarily translate into animal studies or
human clinical trials, it offers potential for further research. The number of clinical trials evaluating
the use of probiotics to manipulate specific bacterial species are limited, especially specific strains
implicated in the CRC, but those that are available in the literature highlight the ability of probiotics
to decrease abundances of Fusobacterium. Through the expression of antimicrobials and competitive
exclusion, probiotics may serve as bio-controlling agents; see Figure 2. Their nontoxicity due to being
natural residents of the gut microbiota further contributes to their safety and potential alternatives
to antibiotics. Overall, the above studies demonstrate the use of probiotics to prevent the growth of
F. nucleatum and to reduce CRC-associated taxa including Fusobacterium, which have been strongly
associated with the development and progression of CRC and, therefore, showing promise in reducing
the overall risk of CRC.Studies evaluating the use of probiotics to inhibit specific CRC-associated
bacterial species have shown promising results for their use as a CRC-preventative strategy. Further
research and clinical trials are needed to investigate the use of probiotics to target bacteria associated
with CRC, positively impacting CRC outcomes.
Figure 2. Proposed mechanism of action by which probiotic supplementation may decrease the risk of
developing colon cancer by inhibiting F. nucleatum through (1) bacteriocin production, (2) competition
for nutrients, (3) co-aggregation, and (4) competitive exclusion through biofilm formation. This figure
was Created with BioRender.
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